Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers

Clinical Cancer Research

Volumn 4, Issue 1, 1998, Pages 189-196

  Peyrat, Jean Philippe ^a   Vanlemmens, Laurence ^a   Fournier, Joëlle ^a   Huet, Guillemette ^b   Révillion, Françoise ^a   Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTRADIOL RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031929625     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1-15, 1992.
2. Gasparini, G., Pozza, F., and Harris, A. L. Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 1206-1219, 1993.
3. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
4. Lane, D. P., and Benchimol, S. p53: oncogene or anti-oncogene? Genes Dev., 4: 1-8, 1990.
5. Duffy, M. J. Urokinase-type plasminogen activator and malignancy. Fibrinolysis, 7: 295-302, 1993.
6. Duffy, M. J. Proteases as prognostic markers in cancer. Clin. Cancer Res., 2: 613-618, 1996.
7. Borg, A., Lennerstrand, J., Stenmark-Askmalm, M., Fernö, M., Brisfors, A., Ohrvik, A., Stal, O., Killander, D., Lane, D., and Brundell, J. Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br. J. Cancer, 71: 1013-1017, 1995.
8. Fernö, M., Bendahl, P. O., Borg, A., Brundell, J., Hirschberg, L., Olsson, H., and Killander, D. Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur. J. Cancer, 32A: 793-801, 1996.
9. Contesso, G., Mouriesse, H., Friedman, S., Genin, J., Sarrazin, D., and Rouesse, J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1010 patients uniformly treated at Institute Gustave Roussy. J. Clin. Oncol., 5: 1378-1386, 1987.
10. Bonneterre, J., Peyrat, J. P., Beuscart, R., and Demaille, A. Prognostic significance of Insulin-like growth factor 1 receptors in human breast cancer. Cancer Res., 50: 6931-6935, 1990.
11. Koenders, T., and Thorpe, S. M. On behalf of the EORTC receptor study group. Standardization of steroid receptor assays in human breast cancer. IV: Long-term within and between laboratory variation of estrogen and progesterone receptor assays. Eur. J. Cancer Clin. Oncol., 22: 945-953, 1986.
12. Peyrat, J-P., Bonneterre, J., Beuscart, R., Djiane, J., and Demaille, A. Insulin-like growth factor 1 receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res., 48: 6429-6433, 1988.
13. Cox, D. R. Regression models and lifetables. J. R. Stat. Soc., 34: 187-200, 1972.
14. Peyrat, J-P., Bonneterre, J., Lubin, R., Vanlemmens, L., Fournier, J., and Soussi, T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet, 345: 621-622, 1995.
15. Allred, D. C., Clark, G. M., Elledge, R., Fuqua, S. A. W., Brown, R. W., Chamness, G. C., Osborne, C. K., and McGuire, W. L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
16. Isola, J., Visakorpi, T., Holli, K., and Kallioniemi, O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
17. Silvestrini, R., Benini, E., Daidone, M. G., Veneroni, S., Boracchi, P., Cappelletti, V., Di Fronzo, G., and Veronesi, U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 85: 965-970, 1993.
18. Thor, A. D., Moore, D. H., II, Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L. C., Mayall, B. H., and Smith, H. S. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
19. Thor, A. D., and Yandell, D. W. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J. Natl. Cancer Inst., 85: 176-171, 1993.
20. Rosen, P. P., Lesser, M. L., Arroyo, C. D., Cranor, M., Borgen, P., and Norton, L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J. Clin. Oncol., 13: 821-830, 1995.
21. Ostrowski, J. L., Sawan, A., Henry, L., Wright, C., Henry, J. A., Hennessy, C., Lennard, T. J. W., Angus, B., and Home, C. H. W. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J. Pathol., 164: 75-81, 1991.
22. Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A., and Millis, R. R. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24: 469-476, 1993.
23. Thorlacius, S., Börresen, A. L., and Eyfjörd, J. E. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res., 53: 1637-1641, 1993.
24. Andersen, T. I., Holm, R., Nesland, J. M., Heimdal, K. R., Ottestad, L., and Borresen, A. L. Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68: 540-548, 1993.
25. Stenmark-Askmalm, M., Stäl, O., Sullivan, S., Ferraud, L., Sun, X. F., Carstensen, J., and Nordenskjöld, B. Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. Eur. J. Cancer, 30A: 175-180, 1994.
26. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbareschi, M., Boracchi, P., Marubini, E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
27. Elledge, R. M., Clarck, G. M., Fuqua, S. A. W., Yu, Y. Y., and Allred, D. C. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res., 54: 3752-3757, 1994.
28. Saitoh, S., Cunningham, J., De Vries, E. M. G., McGovern, R. M., Schroeder, J. J., Hartmann, A., Blaszyk, H., Wold, L. E., Schaid, D., Sommer, S. S., and Kovach, J. S. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene, 9: 2869-2875, 1994.
29. Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Harezga, B., and Osborn, M. p53 protein and vimentin in invasive ductal NOS breast carcinoma: relationship with survival and sites of metastases. Eur. J. Cancer, 30A: 1527-1534, 1994.
30. Wiltschke, C., Kindas-Muegge, I., Steininger, A., Reiner, A., Reiner, G., and Preis, P. N. Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J. Cancer Res. Clin. Oncol., 120: 737-742, 1994.
31. Cunningham, J. M., Ingle, J. N., Jung, S. H., Cha, S. S., Wold, L. E., Farr, G., Witzig, T. E., Krook, J. E., Wieand, H. S., and Kovach, J. S. p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J. Natl. Cancer Inst., 86: 1871-1873, 1994.
32. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
33. Home, G. M., Anderson, J. J., Tiniakos, D. G., McIntosh, G. G., Thomas, M. D., Angus, B., Henry, J. A., Lennard, T. W. J., and Home, C. H. W. p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunhistochemistry. Br. J. Cancer, 73: 29-35, 1996.
34. Sjögren, S., Inganäs, M., Norberg, T., Lindgren, A., Nordgren, H., Holmberg, L., and Bergh, J. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer Inst., 88: 173-182, 1996.
35. Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H., and Graeff, H. Urokinase (uPA), and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
36. Duffy, M. J., Reilly, D., O'Sullivan, C., O'Higgins, N., Fennelly, J. J., and Andreasen, P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res., 50: 6827-6829, 1990.
37. Foekens, J. A., Schmitt, M., Van Putten, W. L. J., Peters, H. A., Bontenbal, M., Jänicke, F., and Klijn, J. G. M. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52: 6101-6105, 1992.
38. Bouchet, C., Spyratos, F., Martin, P. M., Hacène, K., Gentile, A., and Oglobine, J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br. J. Cancer, 69: 398-405, 1994.
39. Duggan, C., Maguire, T., McDermott, E., O'Higgins, N., Fennelly, J. J., and Duffy, M. J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer, 61: 597-600, 1995.
40. Benraad, T. J., Geurts-Moespot, J., Grondahl-Hansen, J., Schmitt, M., Heuvel, J. J. T. M., de Witte, J. H., Foekens, J. A., Leake, R. E., Brünner, N., and Sweep, C. G. J. Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/Biomed-1 workshop. Eur. J. Cancer, 32A: 1371-1381, 1996.
41. Grondahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brünner, N., Mouridsen, H. T., Dano, K., and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53: 2513-2521, 1993.